Received Approval Notification for Clinical Trials of Adsorbed Tetanus Vaccine
December 4, 2024
Source: drugdu
31
On December 2, Walvax Biologics announced that its joint application with its holding subsidiary, Yuxi Walvax Biotechnology Co., Ltd., for clinical trials of an adsorbed tetanus vaccine has recently received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. After review, the adsorbed tetanus vaccine accepted on September 2, 2024, complies with the relevant requirements for drug registration and is approved to conduct clinical trials for the prevention of tetanus.
https://finance.eastmoney.com/a/202412023256655359.html
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- 1 medical device enters the priority approval green channel December 4, 2024
- Artificial cochlear implant leader, impacting IPO! December 4, 2024
- Three giants of IL-23, “making a big splash” in the ulcerative colitis market December 4, 2024
- China’s bispecific antibodies compete in the multi-billion dollar race December 4, 2024
- Xiansheng Pharmaceutical’s Innovative Brain Cell Protection Drug Approved for Market December 4, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
